United Therapeutics (NSDQ:UTHR) today announced first-quarter results that came in well ahead of the consensus forecast. The Research Triangle Park, N.C.-based company posted profits of $28.3 million, or 61¢ per share, on sales of $379.1 million for the three months ended March 31, 2021, for a -79.4% bottom-line slide on sales growth of 6.4%. Adjusted […]
Kala Pharmaceuticals rises before hours on mixed bag Q1
Kala Pharmaceuticals (NSDQ:KALA) announced shares ticked up before hours today on first-quarter results that were mixed compared to the consensus forecast. The Watertown, Mass.-based company posted losses of -$30.4 million, or -49¢ per share, on sales of $3.2 million for the three months ended March 31, 2021, for a -38.5% bottom-line slide despite revenues that […]
Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.
Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S. Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to […]
Most pharma executives see digital drug delivery as important, Molex says
A survey conducted by Molex and its Phillips-Medisize medical device delivery division highlights the importance of digitized drug delivery. Lisle, Ill.-based Molex and Phillips-Medisize commissioned Dimensional Research to poll 215 pharmaceutical professionals who are stakeholders in a range of digital drug delivery devices, according to a news release. Those devices are designed to provide a […]
Smiths Medical partners with Ivenix on infusion management suite
Smiths Medical announced today that it partnered with Ivenix on infusion management. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to “revolutionize” infusion management and improve patient safety while meeting the needs of healthcare providers, according to a news release. Boston-based Ivenix develops what it touts as “the first and only […]
Gyroscope Therapeutics launches IPO roadshow
Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Gyroscope expects pricing for the IPO to range between $20 and $22 per […]
FDA approves higher dosage of naloxone nasal spray
The FDA announced today that it approved a higher dose of naloxone hydrochloride nasal spray to treat opioid overdose. Previously, the FDA had approved 2 mg and 4 mg naloxone nasal spray products, but the newly approved product — Kloxxado from Hikma Pharmaceuticals — delivers 8 mg of naloxone into the nasal cavity, according to […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
Dexcom dips after hours despite Street-beating Q1, raised guidance
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast. DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. The San Diego-based glucose monitoring technology developer posted […]
Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes. Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to […]
